| Title : Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications - Baladi_2000_Clin.Ther_22_1549 |
| Author(s) : Baladi JF , Bailey PA , Black S , Bouchard RW , Farcnik KD , Gauthier S , Kertesz A , Mohr E , Robillard A |
| Ref : Clin Ther , 22 :1549 , 2000 |
| Abstract : Baladi_2000_Clin.Ther_22_1549 |
| ESTHER : Baladi_2000_Clin.Ther_22_1549 |
| PubMedSearch : Baladi_2000_Clin.Ther_22_1549 |
| PubMedID: 11192146 |
Baladi JF, Bailey PA, Black S, Bouchard RW, Farcnik KD, Gauthier S, Kertesz A, Mohr E, Robillard A (2000)
Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications
Clin Ther
22 :1549
Baladi JF, Bailey PA, Black S, Bouchard RW, Farcnik KD, Gauthier S, Kertesz A, Mohr E, Robillard A (2000)
Clin Ther
22 :1549